QMS Medi AGM: FY26 Standalone Revenue ₹152 Cr, Consolidated ₹173 Cr; 5% Dividend Proposed
QMS Medical Allied Services Limited's AGM on September 30, 2026, reported FY26 standalone revenue of ₹152.30 crore and consolidated revenue of ₹172.88 crore. A 5% final dividend was proposed. The company signed a 5-year distribution agreement with HEINE Optotechnik starting January 1, 2027.
The financial results show moderate growth, and the new distribution agreement, while positive, will take effect in the next fiscal year. The AGM itself is a routine event.
The announcement reports growth in both standalone and consolidated revenues, a proposed dividend, and a significant new distribution agreement, all positive indicators for the company.
QMS Medical Allied Services Limited held its 09th Annual General Meeting (AGM) on September 30, 2026, through Video Conferencing. The meeting, chaired by Mr. Mahesh Pahalraj Makhija, commenced at 02:30 PM IST and concluded at 02:51 PM IST.
During the AGM, the Chairman presented the financial performance for FY 2025-26. Standalone revenue was ₹152.30 crore, a 5.1% increase from ₹144.87 crore in FY 2024-25, with EBITDA at ₹20.50 crore and net profit at ₹6.69 crore. Consolidated revenue, including Saarathi Healthcare Private Limited, grew by 10.8% to ₹172.88 crore from ₹156.01 crore in the previous fiscal, with EBITDA at ₹25.88 crore and net profit at ₹11.92 crore.
The Board recommended a final dividend of 5% (₹0.50 per equity share) for FY 2025-26, subject to member approval. The company highlighted its product portfolio of over 900 SKUs and 32,380 healthcare camps conducted in FY 2025-26. Strategic developments included migration to the NSE Mainboard in June 2026, making Saarathi Healthcare a wholly-owned subsidiary, and a proposed Composite Scheme involving Health Care at Home India and Saarathi Healthcare.
Furthermore, on August 27, 2026, QMS Medi signed a five-year exclusive marketing and distribution agreement with HEINE Optotechnik, Germany, making it the sole distributor in India for their covered portfolio from January 1, 2027, to December 31, 2031. The company also noted its proposed investment in BeamOptics Scientific and the expansion of its consumer healthcare brand, Q Devices.
The AGM transacted ordinary business, including the adoption of standalone and consolidated financial statements for FY 2025-26, the re-appointment of Mr. Mahesh Pahalraj Makhija, and the declaration of the final dividend. Special business included the regularization of Mr. Pranav Manhar Badheka as an Additional Independent Director and approval of material related party transactions with Saarathi Healthcare Private Limited.
What to do with a filing like this
QMS Medical Allied Services Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by QMS Medical Allied Services Limited. Read the original for the full detail.